Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: A randomized, double-blind, placebo-controlled trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The mechanisms underlying central neuropathic pain are poorly understood. Pain inhibitory mechanisms including sertononergic and norepinephrine systems may be dysfunctional. In this randomized, double-blinded, placebo-controlled trial we evaluated the effects of duloxetine on pain relief (spontaneous pain and evoked pain), tolerability, health status, and quality of life in patients with central pain related to cerebrovascular lesions or spinal cord lesions. At baseline and eight weeks following start of treatment subjects were evaluated with standard measures of efficacy: pain intensity (primary efficacy variable), quantitative sensory testing, health status and quality of life (secondary efficacy variables). Forty-eight patients received escalating doses of either duloxetine (60 and 120mg/day) or matching placebo capsules. In both groups, patients started with 1 capsule per day. If pain relief was insufficient, patients were titrated to a higher dose. A trend towards a decrease in mean pain score after eight weeks was observed for duloxetine treatment (p=0.056). Duloxetine alleviated dynamic (p=0.035) and cold allodynia (p<0.001) significantly better than placebo. Tactile pain and pressure pain thresholds did not improve significantly. The duloxetine group showed a significant improvement for the bodily pain domain of the SF36 (p=0.035). No significant differences were observed in the other domains of the SF36, the Pain Disability Index, and the EQ-5D. While this trial showed no significant effect on pain intensity, duloxetine revealed a biologic effect. It would be worthwhile to suspend our judgement and to perform more studies to evaluate the role of duloxetine in modulation of the symptoms of central neuropathic pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
McHorney, C. A., Ware, J. E., Rachel Lu, J. F., & Sherbourne, C. D. (1994) · Medical Care · doi:10.1097/00005650-199401000-00004 · Cited by 4,458
The induction of pain: an integrative review
Millan, M. J. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00048-3 · Cited by 1,774 · cited 2×
“Additionally, pain inhibitory mechanisms including both serotonergic and norepinephrine systems may be dysfunctionally contributing to the central sensitization and hyperexcitability of the spinal and supraspinal transmitting pathways [24,28,39,40].”
BackgroundVariations in population health status: results from a United Kingdom national questionnaire survey
Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998) · BMJ · doi:10.1136/bmj.316.7133.736 · Cited by 1,059
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938 · cited 1×
“The numbers needed to treat (NNT) per patient with a reduction of pain by at least 30% or 50%, respectively, are reported along with their confidence intervals [1,3].”
BackgroundTreatment allocation by minimisation
Altman, D. G., & Bland, J. M. (2005) · BMJ · doi:10.1136/bmj.330.7495.843 · Cited by 550
Russell, J. I., Mease, P. J., Smith, T. R., Kajdasz, D. K., Wohlreich, M. M., Detke, M. J., Walker, D. J., Chappell, A. S., & Arnold, L. M. (2008) · Pain · doi:10.1016/j.pain.2008.02.024 · Cited by 367
The Pain Disability Index: Factor structure and normative data
Chibnall, J. T., & Tait, R. C. (1994) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/0003-9993(94)90082-5 · Cited by 338 · cited 11×
“The SF36 questionnaire compromises 36 items, which fall into eight domains including physical functioning (Physical), role-physical functioning (Role), bodily pain (Pain), general health perception (Health), energy/vitality (Vitality), social functioning (Social), role-emotional functioning (Emotional), and mental hea…”
MethodInfluential
Cited by
Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms
Jensen, T. S., & Finnerup, N. B. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70102-4 · Cited by 976
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565
Neuropathic Pain: Principles of Diagnosis and Treatment
Gilron, I., Baron, R., & Jensen, T. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.01.018 · Cited by 540
Moulin, D., Boulanger, A., Clark, A., Clarke, H., Dao, T., Finley, G., Furlan, A., Gilron, I., Gordon, A., Morley-Forster, P., et al. (2014) · Pain Research and Management · doi:10.1155/2014/754693 · Cited by 529
Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Schimrigk, S., Marziniak, M., Neubauer, C., Kugler, E. M., Werner, G., & Abramov-Sommariva, D. (2017) · European Neurology · doi:10.1159/000481089 · Cited by 136
Metadata
- Authors
- Vranken, J. H., Hollmann, M. W., van der Vegt, M. H., Kruis, M. R., Heesen, M., Vos, K., Pijl, A. J., & Dijkgraaf, M. G. W.
- Venue
- Pain
- Published
- 2011-02
- Volume
- 152
- Issue
- 2
- Pages
- 267-273
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2052654921
- Cited by
- 137
- References
- 8
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: A randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/j.pain.2010.09.005
- The paper
- Vranken, J. H., Hollmann, M. W., van der Vegt, M. H., Kruis, M. R., Heesen, M., Vos, K., Pijl, A. J., & Dijkgraaf, M. G. W. (2011). Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: A randomized, double-blind, placebo-controlled trial. Pain. https://doi.org/10.1016/j.pain.2010.09.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.